APOE and Alzheimer disease: A separate phase 2 clinical trial (NCT04693520) is currently examining the impact of oral ALZ-801 on individuals with early AD who possess the APOE4/4 or APOE3/4 genotype and have biomarkers indicating the presence of core AD pathology.